<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390676</url>
  </required_header>
  <id_info>
    <org_study_id>AHX-01-006</org_study_id>
    <nct_id>NCT00390676</nct_id>
  </id_info>
  <brief_title>A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine</brief_title>
  <official_title>A Phase 1, Multicenter, Dose-Escalation Study to Investigate the Safety and Tolerability of ADH-1 in Combination With 1) Carboplatin or 2) Docetaxel or 3) Capecitabine in Subjects With N-Cadherin Positive, Advanced Solid Tumors (Adherex Protocol Number AHX-01-006)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adherex Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Oncology Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Adherex Technologies, Inc.</source>
  <brief_summary>
    <textblock>
      N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer
      progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study
      will test the safety and effects of the combination ADH-1 and carboplatin or ADH-1 and
      docetaxel or ADH-1 and capecitabine in subjects with specific incurable, solid tumors with a
      protein biomarker called N-cadherin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADH -1 and carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADH -1 and docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADH -1 and capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed written informed consent

          -  Male and female patients &gt; or = 18 years of age with a solid tumor(s) that is locally
             advanced or metastatic for which single agent carboplatin, or docetaxel or
             capecitabine would be appropriate

          -  Measurable disease

          -  Immunohistochemical evidence of N-cadherin expression in tumor tissue

          -  Adequate performance status and organ function, as evidenced by hematological and
             biochemical blood testing and ECG

        Exclusion criteria:

          -  Receipt of ADH-1 prior to this clinical study

          -  Chemotherapy, radiotherapy, or any other investigational drug within 4 weeks before
             study entry

          -  History of spinal cord compression, or history of primary brain tumor(s) or brain
             metastases (known or suspected) unless any lesions have completely resolved following
             appropriate treatment and there has been no recurrence for at least 6 months

          -  History of tumors that have shown clinically significant evidence of active bleeding
             within 12 weeks before study entry

          -  Stroke, major surgery, or other major tissue injury within 4 weeks before study entry

          -  Uncontrolled congestive heart failure, coronary artery disease, or life threatening
             arrhythmias; myocardial infarction within 12 months; significant electrocardiogram
             (ECG) abnormalities, or known hypercoagulable states
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Florida</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Oncology &amp; Hematology, P.A</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists - Vancouver Cancer Center</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.adherex.com</url>
    <description>Adherex Technologies Inc. Corporate Homepage</description>
  </link>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2006</study_first_posted>
  <last_update_submitted>December 27, 2010</last_update_submitted>
  <last_update_submitted_qc>December 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Study Manager</name_title>
    <organization>Adherex Technologies</organization>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>tumors</keyword>
  <keyword>anticarcinogenic agents</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>cadherins</keyword>
  <keyword>solid tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

